Lantheus to Present New Data on LNTH-2403 at ASCO Meeting
Lantheus Holdings Inc. shares rose 4.23% and reached a 52-week high amid positive market conditions.
The company will present data on LNTH-2403 at the 2026 American Society of Clinical Oncology Annual Meeting, focusing on its safety and preliminary anti-neoplastic activity for relapsed osteosarcoma. This presentation is scheduled for June 1 and is expected to attract significant attention from clinicians and researchers, potentially offering new treatment options for patients. Additionally, Lantheus will release findings on the real-world use of piflufolastat F 18 in early-stage prostate cancer, further supporting its commitment to innovative solutions in radiopharmaceuticals.
This upcoming presentation at a prestigious conference highlights Lantheus's ongoing efforts in advancing cancer treatment options, which may enhance its market position and investor confidence.
Trade with 70% Backtested Accuracy
Analyst Views on LNTH
About LNTH
About the author

- Acquisition Proposal: Lantheus Holdings is considering a takeover offer from Curium Pharma valued at approximately $7 billion, indicating strong market interest in its nuclear medicine business and potentially prompting a strategic overhaul.
- Negotiation Progress: The two companies are in discussions about a potential deal that could materialize in weeks, although no final decision has been made, reflecting uncertainty about Lantheus's future in the market.
- Market Reaction: Lantheus shares fell nearly 2% in after-hours trading, yet they have surged 54.8% this year, indicating investor confidence in its long-term growth potential despite short-term volatility.
- Valuation Insight: With a current market capitalization of about $6.15 billion, the acquisition proposal's valuation underscores Lantheus's competitiveness in the radiopharmaceutical sector, potentially attracting further investor interest in its future trajectory.
- Acquisition Talks Progress: Lantheus Holdings (LNTH) surged 7.4% following a takeover offer from Curium, valuing the firm at approximately $7 billion, indicating strong market optimism regarding potential transaction outcomes.
- Strong Market Reaction: Following the Bloomberg report, Lantheus's market cap reached $6.2 billion, with investor interest in the potential deal spiking, reflecting a positive outlook on the company's future business prospects.
- Existing Partnership: Lantheus and Curium have an existing partnership, which lays the groundwork for a potential transaction, suggesting possible synergies in business integration between the two firms.
- Stable Financial Outlook: Lantheus reiterated its 2026 revenue outlook of $1.4 billion to $1.45 billion, demonstrating robust financial performance during acquisition discussions, which bolsters investor confidence.
- New Data Presentation: Lantheus Holdings will showcase new radiodiagnostic data at the 2026 Society of Nuclear Medicine and Medical Imaging Annual Meeting from June 1 to June 2 in Los Angeles, aimed at enhancing clinicians' ability to identify and manage diseases.
- Poster Presentation: On June 1, Neal Shore will present on the impact of PSMA-PET with Piflufolastat F18 on prostate cancer management for patients with low or ultra-low PSA levels, emphasizing the significance of this technology in precision medicine.
- Oral Presentation: On June 2, Sangwon Han will discuss the diagnostic performance of 18F-GP1 PET/CT for acute deep vein thrombosis in symptomatic patients, showcasing phase 2 study results that may provide new diagnostic tools for clinical practice.
- Company Background: Lantheus has been focused on radiopharmaceutical development for 70 years, committed to leveraging innovative science to help clinicians better find, fight, and follow diseases, ultimately improving patient outcomes.
- Clinical Research Showcase: Lantheus will present data on LNTH-2403 at the 2026 American Society of Clinical Oncology Annual Meeting, focusing on its safety and preliminary anti-neoplastic activity for relapsed osteosarcoma, potentially offering new treatment options for patients.
- Presentation Schedule: The poster presentation is scheduled for June 1, with poster number 376b, covering pharmacokinetics and radiation dosimetry, which is expected to attract attention from clinicians and researchers alike.
- Real-World Data Analysis: Lantheus will also release findings on the real-world use of piflufolastat F 18 in early-stage prostate cancer, providing valuable data to support clinical practice.
- Company Background: As a leading radiopharmaceutical company, Lantheus has been delivering innovative radiopharmaceutical solutions for 70 years, enabling clinicians to better find, fight, and follow diseases, thereby improving patient outcomes.
- Strong Revenue Performance: Lantheus achieved $377.3 million in revenue for Q1 2026, reflecting year-over-year growth primarily driven by solid performances from PYLARIFY, NEURACEQ, and DEFINITY, indicating the company's ability to maintain stability in a competitive market.
- Product Transition Plan: The company plans to transition PYLARIFY directly to PYLARIFY TRUVU starting in Q4 2026, with significant revenue contributions expected in 2027, highlighting strategic decision-making in product innovation and market adaptability.
- Regulatory Milestone: The FDA approved PYLARIFY TRUVU on March 6, which is expected to enhance production capacity and patient coverage, further solidifying Lantheus's market position in the radiotherapeutic sector.
- Full-Year Performance Outlook: Despite a strong Q1, the CFO reiterated the full-year revenue guidance of $1.4 billion to $1.45 billion for 2026, reflecting the company's cautious stance amid competition and the CEO transition period.
- Significant Earnings Growth: Lantheus Holdings reported Q1 earnings of $118.42 million, translating to $1.80 per share, which marks a substantial increase from last year's $72.95 million and $1.02 per share, indicating enhanced competitiveness in the market.
- Adjusted Earnings Performance: Excluding special items, the company reported adjusted earnings of $95.80 million or $1.46 per share, showcasing a sustained improvement in core business profitability, which further solidifies investor confidence in the company's future growth.
- Slight Revenue Increase: The total revenue for the first quarter reached $377.33 million, up 1.2% from $372.76 million last year, demonstrating resilience and ongoing customer demand despite the modest growth rate in a stable market environment.
- Optimistic Market Outlook: With the improvement in earnings and stable market demand, Lantheus Holdings is poised to maintain its growth momentum in the future, attracting more investor interest in its long-term development potential.









